Friday, August 21, 2020
Concept Map: Various antigens in Membranous Nephropathy
Thursday, August 20, 2020
Topic Discussion: ESRD patients and COVID-19
While we saw several rising cases of AKI associated with COVID-19, the ESKD population was also vulnerable to this virus. With COVID-19, we didn't know if we would see worsening effects on ESRD or beneficial ( given a not so robust immune system in ESRD). But the proximity and being in a closed dialysis unit did put most of them at risk.
Studies from China and Europe on ESKD patients with COVID-19 were limited to small numbers and single centers. One of the first studies from US from CUMC was limited by less then 100 patients as well. It did show poor outcomes of 59 patients where 31% had died.

A Study from UK did discuss the concerns for an urban dialysis center ( on risk of hospitalizations). Of 1530 patients (median age 66 years; 58.2% men) receiving dialysis, 300 (19.6%) developed COVID-19 infection, creating a large demand for isolated outpatient dialysis and inpatient beds. An analysis that included 1219 patients attending satellite dialysis clinics found that older age was a risk factor for infection. COVID-19 infection was substantially more likely to occur among patients on in-center dialysis compared with those dialyzing at home.
A study from the Bronx in NY also showed poor outcomes for hospitalized ESKD patients. Elevated inflammatory markers were associated with in hospital death.
Another UK study also found a high prevalence of seropositivity in the outpatient dialysis units.

Alberici et al.describe their clinical experience with MHD patients cared for at 4 outpatient dialysis facilities that are part of the Brescia Renal COVID Task Force. In a period of 1 month, viral positivity was detected in 94 of their 643 ESRD HD patients (15%). Important findings in the study were the mild form of symptomatology at presentation, the high rate of overall mortality (29%), and emergence of usual risk factors for mortality and acute respiratory distress syndrome in SARS-CoV-2–positive HD patients. In addition, although certain patients were deemed more stable and were managed in the outpatient facility, 3 of those subsequently died, and a substantial portion had significant worsening of their symptoms.

At our health system of over 23 hospitals in NY, we decided to compare the outcomes of ESKD patients to non ESKD patients. The data was from 13 hospitals and our final cohort had 419 (4%) with ESKD and 10,063 (96%) without ESKD.This is the largest study to date.

What did we find:( similar tweetorial by first author Jia Ng)
I want to share our new paper “Outcomes of patients with ESKD hospitalized with COVID-19”. @kidney_int @hofstrakidney @hofstramed @jam_hirsch @rimdamyeloma @mala_sachdeva @sfishbane @kdjhaveri Susana Hong
— Jia Hwei Ng, MD, MSCE (@jiahweing) August 16, 2020
https://t.co/B2jd3RO4lt
[THREAD] pic.twitter.com/4S03hTRHAo
1. Patients with ESKD were older, had a greater percentage self-identified as Black, and more comorbid conditions.
4. The odds of length of stay of seven or more days was higher in the group with compared to the group without ESKD in both the crude (1.62, 95%CI 1.27 - 2.06) and in the adjusted analysis (1.57, 95% 1.22 - 2.02)
5. We conducted stratified analyses to investigate the risk
factors of death in the subgroups of ESKD and the non-ESKD separately, with the
hypothesis that the risk factors of death and the magnitude of risk factors
would differ between the two groups.
6. For patients without ESKD, the independent risk factors
for in-hospital death increased age, male sex, cardiovascular disease, cancer,
requiring ventilation, requiring vasoactive meds, high blood urea nitrogen, low
albumin, high CRP and high ferritin.
7. The diagnosis of hypertension and use of an ACE inhibitor
or ARB were associated with a lower risk of in-hospital death in the non-ESKD
group.
8. Among patients with ESKD, independent risk factors for
in-hospital death were increased age, requiring ventilation and lymphopenia,
elevated BUN and high serum ferritin. Black race was associated with a
significantly lower risk of death among patients with ESKD.
9. The protective effect of HTN in the non-EKSD group, and
the protective effect of Black race in the ESKD group defy easy explanation. Perhaps APOL1 has some protective cardiac effect?
10. This is a large cohort of hospitalized
patients with #COVID-19 comparing ESKD and non-ESKD in a diverse patient population.
We had prespecified operational definitions for exposures, covariates and
outcomes, as well as rigorous adjudication by two independent reviewers for
ESKD exposure.
11. What limitations do we have?--Despite the larger size of this study compared to other reports, the ESKD sample may still have been relatively underpowered to find other statistically significant risk factors in mortality. Also there was inability to adjust for remdesivir and dexamethasone. As the evidence of these 2 drugs came after the surge of #COVID-19 cases in our health system, only a small proportion of patients received these drugs.
12. We had 11 PD patients in our admitted cohort. This was also published in a special report as well. Of 419 hospitalized patients with ESKD, 11 were on chronic PD therapy (2.6%). Among those 11, 3 patients required mechanical ventilation, 2 of whom died. Of the entire cohort, 9 of the 11 patients (82%) were discharged alive. While fever was a common presentation, more than half of our patients also presented with diarrhea. Interestingly, 3 patients were diagnosed with culture-negative peritonitis during their hospitalization. Seven patients reported positive SARS-CoV-2 exposure from a member of their household.
In conclusion, among patients hospitalized with COVID-19, those with ESKD had a higher rate of in-hospital death compared to those without ESKD.
Two recent studies also show the outpatient HD infection and admission rates. A study published in AJKD from Canada showed from universal screening, 4.6% were infected.

Another French study in KI showed a low incidence of infection of 3.3% in a large >40,000 dialysis patients. Older age, low albumin, and cardiac disease were risk factors for mortality.

Taken together, the results suggest both a need for further research and the continued need for careful infection control procedures in the ESKD population at risk for #COVID-19.
Wednesday, August 5, 2020
Detective Nephron: Next venture


Sunday, August 2, 2020
Topic Discussion: Pyelonephritis but no Urinary Tract Infection?
Can this exist without any signs of an urinary track infection?
A study published in NDT looked prospectively of over 200 cases of acute pyelonephritis.
What did they find?
No differences were noted in patients with positive or negative CT findings in terms of fevers, and wbc counts, pyuria, urine cultures and symptoms.
Sunday, July 19, 2020
Topic Discussion: COVID and Kidneys- the biopsy experience
We have now established the incidence being around 30-40% in the US.
This figure from an article in JASN summarizes the potential way the SARS-Cov2 might be effecting the kidney

Two recent biopsy series from Columbia and Northwell Nephrology showed the variety of pathology reported in COVID-19


In addition, an autopsy series (specific) to the kidneys showed ATN only. Finally, in KI, a series of anti GBM were reported in UK related to COVID-19
All recent papers added interesting few things to the ongoing literature.
1. ATN is by far the most common presentation for AKI( if not pre renal)- even in transplanted kidney. Pigment nephropathy from myoglobin or hemoglobin is rare. Vitamin C overdose induced oxalate nephropathy is rare.
2. Podocytopathies( MCD and cGN) are the most common glomerular findings
3. Other glomerular diseases are a varied amount( TMA, ANCA, Membranous GN, anti GBM)
4. The virus was not found in the kidney with immunohistochemistry in all 3 studies.
Does the kidney get infected?- time will tell.. data is mixed
Sunday, June 21, 2020
10 Years of Nephrology Social Media
Few of us started blogging at National conferences, some of us tweeting like a storm. Finally, the academic community noticed this and soon ASN, NKF and all wanted tweets and blogs of their events. The first landmark paper summarizing some of this was in AJKD in 2011.
Following that, was the birth of AJKDblog or then called eAJKD. This allowed for more collaboration and more social media to flourish in nephrology and leading to the ultimate- Nephmadness ( mastermind game by the Topf Sparks team) in 2013.
After 2013, nothing was stopping nephrology to take the lead in social media.
From NephJC to tweetorials to whatsApp to creation of NSMC-- happening so fast and furious!
Nephrologists quickly stormed the social media world to lead and show how it's done!
In NDT is a brief tutorial for how to be social media savvy.
Academic journals- AJKDBlog
Journal club- NephJC
Well ironed blogs- Renal Fellow Network
Online Successfully run interactive game for over 7 years- Nephmadness
Online academy of educators for future social media wannabees- NSMC
Every fellowship program trying to have a twitter account and social media presence.
What else can you ask for?
All this is summarized in recent issue in Seminars in Nephrology by guest editor Joel Topf and includes all various aspects of the social media
Here is a nice tweetorial by Chan on the entire issue
Seminars in Nephrology has an entire issue devoted to social media in the discipline of nephrology.— Teresa Chan (@TChanMD) June 20, 2020
The mastermind @kidney_boy highlights the contents here:https://t.co/1XhYQLpEyS pic.twitter.com/OQs757SxmI
Introduction to social media
Tweet or not to tweet
Twitter based journal clubs
Tweetorials
Podcasting
Newsletters
Visual abstracts
Slack
Semi-private Apps ( WhatsApp)
FOAM quality
NSMC
Congratulation to the nephrology community to being leaders in education via social media in medicine!
Saturday, May 16, 2020
Topic Discussion: Use of immunotherapy in ESRD patients
One study comes from Boston published in AJKD, with a database search leading to 18 patients: overall, six patients (32%) experienced irAEs and two (11%) experienced an irAE of grade 3/4 toxicity (pneumonitis, myocarditis).
Another study from New York published in Kidney 360, with a database search lead to 8 patients: only 2 patients (25%) experienced irAEs overall. A literature review done in that paper also found another 26 patients have previously been described in the literature, with the majority of them from Italy and China. Interestingly, 27% of these patients were on dialysis as a result of a rejected kidney transplant due to ICI therapy, and then continued to receive ICI. Over 80% of the patients had either partial or complete response to treatment. Aside from the kidney transplant rejection preceding dialysis, a minimal number of patients had a grade 2, 3, or 4 adverse immunotherapy related event (15%). In the general population, between 40-60% of patients receiving ICIs experience irAEs at some point during therapy.
Again, due to smaller numbers, we cannot be sure the effects of ICI in ESRD patients but it appears that the rate of irAEs appears similar to general population.

